The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma

International Journal of Gynecological Cancer

Volumn 21, Issue 8, 2011, Pages 1479-1485

  Hasegawa, Kiyoshi ^a   Kato, Rina ^a   Torii, Yutaka ^a   Ichikawa, Ryoko ^a   Oe, Shuko ^a   Udagawa, Yasuhiro ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemosensitivity; ERCC1; Immunohistochemistry; Prognosis; Uterine cervical adenocarcinoma

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME; UTERINE CERVICAL ADENOCARCINOMA; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; AGED; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; UTERINE CERVIX; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; AGED; CERVIX UTERI; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84857490668     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31822265e7     Document Type: Article

References (17)

1. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286-2291. (Pubitemid 34753602)
2. Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007;98:1336-1343. (Pubitemid 47241754)
3. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355: 983-991. (Pubitemid 44343542)
4. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16:309-316. (Pubitemid 28041614)
5. Kim MK, Cho K-J, Kwan GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 2008;44:54-60. (Pubitemid 350256935)
6. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007;18:522-528. (Pubitemid 46359633)
7. Steffensen KD, Waldstrom M, Jakobsen A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:820-825.
8. Scheil-Bertram S, Tylus-Schaaf P, du Bois A, et al. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecol Oncol. 2010;119:325-331.
9. Britten RA, Liu D, Tessier A, et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer. 2000;89:453-457.
10. Park J-S, Jeon EK, Chun SH, et al. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO 2B uterine cervix cancer. Gynecol Oncol. 2011;120:275-279.
11. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25:2747-2754. (Pubitemid 47123183)
12. Thigpen JT. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J. 2003;9:425-432.
13. Tattersall MH, Ramirez C, Coppleson M. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastasis. Gynecol Oncol. 1992;46:176-181.
14. Takeshima N, Umayahara K, Fujiwara K, et al. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer. Gynecol Oncol. 2006;103:618-622. (Pubitemid 44602177)
15. Lahousen M, Haas J, Pickel H, et al. Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: a randomized, prospective, multicenter trial. Gynecol Oncol. 1999;73:196-201. (Pubitemid 29215731)
16. Monk BJ, Sill MW, McMeekin DS, et al. A randomized phase III trial of four cisplatin containing doublet combination in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study. ASCO Proc. 2008;(Abstract No. LBA5504).
17. Quinn MA, Benedet JL, Odicino F, et al. FIGO: 26th volume of the annual reports on the results of treatment in gynecological cancer. Int J Gynecol Obstet. 2006;95:S43-S103.